15 Month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery
Open Access
- 1 August 2002
- journal article
- clinical trial
- Published by BMJ in Sexually Transmitted Infections
- Vol. 78 (4) , 267-270
- https://doi.org/10.1136/sti.78.4.267
Abstract
Objectives: To study mother to child HIV-1 transmission (MTCT) and infant mortality following benzalkonium chloride (BC) disinfection. Methods: A randomised, double blind phase II placebo controlled trial. Women testing positive for HIV-1 infection in prenatal care units in Abidjan, Côte d’Ivoire, and Bobo-Dioulasso, Burkina Faso, from November 1996 to April 1997 were eligible, with their informed consent. Women self administered daily a vaginal suppository of 1% BC (53) or matched placebo (54) from 36 weeks of pregnancy, plus a single dose during labour. The neonate was bathed with 1% BC solution or placebo within 30 minutes after birth. MTCT rate was assessed based on repeated polymerase chain reaction (PCR) and serology results. For the present analysis, children were followed up to 15 months. Results: A total of 107 women were enrolled. Of 103 eligible liveborn children, 23 were HIV infected, 75 uninfected, and five of indeterminate status. MTCT transmission rate was 24.2% overall (95% confidence interval (CI): 14.3% to 30.4%). On an intent to treat basis, the transmission rate did not differ between the two groups (23.5%, CI 13.8 to 38.5, in the BC group and 24.8%, CI 15.0 to 39.6, in the placebo group at 15 months). Similarly, there was no difference in mortality at 15 months (22.9%, CI 13.7 to 36.9, in the BC group and 16.5%, CI 9.0 to 29.4, in the placebo group). Conclusion: This analysis failed to suggest any benefit of BC disinfection on mother to child HIV transmission or perinatal and infant mortality.Keywords
This publication has 25 references indexed in Scilit:
- Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studiesAIDS, 2001
- Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000AIDS, 2000
- Short‐Course Antenatal Zidovudine Reduces Both Cervicovaginal Human Immunodeficiency Virus Type 1 RNA Levels and Risk of Perinatal TransmissionThe Journal of Infectious Diseases, 2000
- Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant women in west Africa: ANRS 049b phase II randomized, double blinded placebo controlled trial. DITRAME Study GroupSexually Transmitted Infections, 1999
- Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in RwandaPublished by American Academy of Pediatrics (AAP) ,1999
- 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trialThe Lancet, 1999
- Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twinsThe Journal of Pediatrics, 1995
- Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues Ghent (Belgium), 17–20 February 1992AIDS, 1993
- Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labourThe Lancet, 1992
- Survival and Disinfectant Inactivation of the Human Immunodeficiency Virus: A Critical ReviewClinical Infectious Diseases, 1991